메뉴 건너뛰기




Volumn 2, Issue 6, 2011, Pages 448-456

Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type2 diabetes

Author keywords

Exenatide; Japan; Type2 diabetes mellitus

Indexed keywords

1,5 ANHYDROSORBITOL; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; PLACEBO;

EID: 84859850557     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00137.x     Document Type: Article
Times cited : (14)

References (30)
  • 1
    • 84859849961 scopus 로고    scopus 로고
    • Ministry of Health, Labor, and Welfare. Ministry of Health, Labor, and Welfare, Tokyo, Japan, Available at: (Last accessed on 2010, October 15). (Japanese).
    • Ministry of Health, Labor, and Welfare. National Survey of Diabetes 1997. Ministry of Health, Labor, and Welfare, Tokyo, Japan, 1998. Available at: (Last accessed on 2010, October 15). (Japanese).
    • (1998) National Survey of Diabetes 1997
  • 2
    • 0036711306 scopus 로고    scopus 로고
    • Diabetes trends in Japan
    • Kawamori R. Diabetes trends in Japan. Diabetes Metab Res Rev 2002; 18(Suppl. 3): S9-S13.
    • (2002) Diabetes Metab Res Rev , vol.18 , Issue.SUPPL. 3
    • Kawamori, R.1
  • 3
    • 12944310061 scopus 로고    scopus 로고
    • Ministry of Health, Labor, and Welfare. Ministry of Health, Labor, and Welfare, Tokyo, Japan, Available at: (last accessed on 2010, October 15). (Japanese).
    • Ministry of Health, Labor, and Welfare. National Survey of Diabetes 2002. Ministry of Health, Labor, and Welfare, Tokyo, Japan, 2003. Available at: (last accessed on 2010, October 15). (Japanese).
    • (2003) National Survey of Diabetes 2002
  • 4
    • 84864840029 scopus 로고    scopus 로고
    • Ministry of Health, Labor, and Welfare. Ministry of Health, Labor, and Welfare, Tokyo, Japan, Available at (last accessed on 2010, October 15). (Japanese).
    • Ministry of Health, Labor, and Welfare. Outline of the National Health and Nutrition Survey. Ministry of Health, Labor, and Welfare, Tokyo, Japan, 2007. Available at (last accessed on 2010, October 15). (Japanese).
    • (2007) Outline of the National Health and Nutrition Survey
  • 5
    • 0032972676 scopus 로고    scopus 로고
    • Racial and ethnic differences in glycemic control of adults with type 2 diabetes
    • Harris MI, Eastman RC, Cowie CC, et al. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999; 22: 403-408.
    • (1999) Diabetes Care , vol.22 , pp. 403-408
    • Harris, M.I.1    Eastman, R.C.2    Cowie, C.C.3
  • 6
    • 0347133334 scopus 로고    scopus 로고
    • Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes
    • Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-342.
    • (2004) JAMA , vol.291 , pp. 335-342
    • Saydah, S.H.1    Fradkin, J.2    Cowie, C.C.3
  • 7
    • 73349083380 scopus 로고    scopus 로고
    • Diabetes in Japan: a review of disease burden and approaches to treatment
    • Neville SE, Boye KS, Montgomery WS, et al. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev 2009; 25: 705-716.
    • (2009) Diabetes Metab Res Rev , vol.25 , pp. 705-716
    • Neville, S.E.1    Boye, K.S.2    Montgomery, W.S.3
  • 8
    • 12444289448 scopus 로고    scopus 로고
    • Oral antihyperglycemic therapy for type 2 diabetes mellitus
    • Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005; 172: 213-226.
    • (2005) CMAJ , vol.172 , pp. 213-226
    • Cheng, A.Y.1    Fantus, I.G.2
  • 9
    • 77950123038 scopus 로고    scopus 로고
    • Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications
    • e9-18.
    • Bergenstal RM, Bailey CJ, Kendall DM. Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Am J Med 2010; 123: 374. e9-18.
    • (2010) Am J Med , vol.123 , pp. 374
    • Bergenstal, R.M.1    Bailey, C.J.2    Kendall, D.M.3
  • 10
    • 0037850667 scopus 로고    scopus 로고
    • Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes
    • Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 2370-2377.
    • (2003) Diabetes Care , vol.26 , pp. 2370-2377
    • Fineman, M.S.1    Bicsak, T.A.2    Shen, L.Z.3
  • 11
    • 7444228521 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control over 30weeks in sulfonylurea-treated patients with type 2 diabetes
    • Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
    • (2004) Diabetes Care , vol.27 , pp. 2628-2635
    • Buse, J.B.1    Henry, R.R.2    Han, J.3
  • 12
    • 18144401971 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes
    • DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
    • (2005) Diabetes Care , vol.28 , pp. 1092-1100
    • DeFronzo, R.A.1    Ratner, R.E.2    Han, J.3
  • 13
    • 17144371646 scopus 로고    scopus 로고
    • Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
    • Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
    • (2005) Diabetes Care , vol.28 , pp. 1083-1091
    • Kendall, D.M.1    Riddle, M.C.2    Rosenstock, J.3
  • 14
    • 34247195226 scopus 로고    scopus 로고
    • A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
    • Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50: 259-267.
    • (2007) Diabetologia , vol.50 , pp. 259-267
    • Nauck, M.A.1    Duran, S.2    Kim, D.3
  • 15
    • 34247259577 scopus 로고    scopus 로고
    • The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial
    • Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477-485.
    • (2007) Ann Intern Med , vol.146 , pp. 477-485
    • Zinman, B.1    Hoogwerf, B.J.2    Duran Garcia, S.3
  • 16
    • 79961065111 scopus 로고    scopus 로고
    • Improved glycemic control and reduced body weight with exenatide: a double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24weeks
    • Kadowaki T, Namba M, Imaoka T, et al. Improved glycemic control and reduced body weight with exenatide: a double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24weeks. J Diabetes Invest 2011; 2: 210-217.
    • (2011) J Diabetes Invest , vol.2 , pp. 210-217
    • Kadowaki, T.1    Namba, M.2    Imaoka, T.3
  • 17
    • 79251476847 scopus 로고    scopus 로고
    • Report of the Committee on the classification and diagnostic criteria of diabetes mellitus
    • The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus
    • The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
    • (2010) J Diabetes Invest , vol.1 , pp. 212-228
    • Seino, Y.1    Nanjo, K.2
  • 19
    • 33748442464 scopus 로고    scopus 로고
    • Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82weeks in 314 overweight patients with type 2 diabetes
    • Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-447.
    • (2006) Diabetes Obes Metab , vol.8 , pp. 436-447
    • Blonde, L.1    Klein, E.J.2    Han, J.3
  • 20
    • 33947156808 scopus 로고    scopus 로고
    • Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
    • Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007; 29: 139-153.
    • (2007) Clin Ther , vol.29 , pp. 139-153
    • Buse, J.B.1    Klonoff, D.C.2    Nielsen, L.L.3
  • 21
    • 65949122087 scopus 로고    scopus 로고
    • One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial
    • Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009; 32: 762-768.
    • (2009) Diabetes Care , vol.32 , pp. 762-768
    • Bunck, M.C.1    Diamant, M.2    Corner, A.3
  • 22
    • 78649447003 scopus 로고    scopus 로고
    • One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice
    • Buysschaert M, Preumont V, Oriot PR, et al. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab 2010; 36: 381-388.
    • (2010) Diabetes Metab , vol.36 , pp. 381-388
    • Buysschaert, M.1    Preumont, V.2    Oriot, P.R.3
  • 23
    • 65949111736 scopus 로고    scopus 로고
    • Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study
    • Noel RA, Braun DK, Patterson RE. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32: 834-838.
    • (2009) Diabetes Care , vol.32 , pp. 834-838
    • Noel, R.A.1    Braun, D.K.2    Patterson, R.E.3
  • 24
    • 79951704452 scopus 로고    scopus 로고
    • Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis
    • Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33: 2349-2354.
    • (2010) Diabetes Care , vol.33 , pp. 2349-2354
    • Garg, R.1    Chen, W.2    Pendergrass, M.3
  • 25
    • 77955016889 scopus 로고    scopus 로고
    • Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes
    • Girman CJ, Kou TD, Cai B, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 2010; 12: 766-771.
    • (2010) Diabetes Obes Metab , vol.12 , pp. 766-771
    • Girman, C.J.1    Kou, T.D.2    Cai, B.3
  • 26
    • 67649304917 scopus 로고    scopus 로고
    • Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
    • Dore DD, Seegar JD, Chan KA. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25: 1019-1027.
    • (2009) Curr Med Res Opin , vol.25 , pp. 1019-1027
    • Dore, D.D.1    Seegar, J.D.2    Chan, K.A.3
  • 27
    • 79954994764 scopus 로고    scopus 로고
    • A cohort study of acute pancreatitis in relation to exenatide use
    • Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011; 13: 559-566.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 559-566
    • Dore, D.D.1    Bloomgren, G.L.2    Wenten, M.3
  • 28
    • 34250829991 scopus 로고    scopus 로고
    • Eli Lilly Japan K.K. Eli Lilly Japan K.K., Kobe, Japan
    • Eli Lilly Japan K.K. Byetta [package insert]. Eli Lilly Japan K.K., Kobe, Japan, 2010.
    • (2010) Byetta [package insert]
  • 29
    • 38549162147 scopus 로고    scopus 로고
    • Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3years
    • Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3years. Curr Med Res Opin 2008; 24: 275-286.
    • (2008) Curr Med Res Opin , vol.24 , pp. 275-286
    • Klonoff, D.C.1    Buse, J.B.2    Nielsen, L.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.